Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD).
Tobacco smoke is the largest risk factor for COPD, although other factors, including outdoor air pollution, the burning of biomass fuels, exposure to passive smoking and other noxious gases and fumes, combined with genetic disposition, maternal tobacco exposure, and childhood respiratory infections, are important contributors to disease development. Increased exposure to risk factors for COPD (with the rising tobacco epidemic in low-and middleincome countries) and increasing population longevity contribute to the heavy forecasted societal and economic burden worldwide (Lopez-Campos 2016).
Pathology, symptoms, and progress
The pathophysiological effects of COPD are chronic inflammation of the airways and irreversible lung tissue damage, resulting in reduced airflow to the lungs (Szilasi 2006) . COPD is diagnosed when spirometry demonstrates airflow obstruction that is not fully reversible (Qaseem 2011). COPD is a debilitating disease that worsens over time, with frequently reported symptoms of decreased exercise capacity, dyspnoea, and leg fatigue ( 
Comorbidities
COPD co-morbidities are common, and include cardiovascular disease, diabetes, asthma, anxiety, and depression (Eisner 2010; Mannino 2015;Schneider 2010). These increase the overall burden to the individual, as well as to families, caregivers, and health and social care services, a burden that is increasing worldwide (GBD 2015) .
COPD Management
Other than the treatment and prevention of exacerbations, therapy during stable COPD is aimed at reducing progression and managing symptoms. All patients should be offered smoking cessation advice at regular intervals, as this is the main disease-modifying treatment available at present (Vogelmeier 2017). Pharmacotherapy consists of short-acting and long-acting bronchodilator inhalers, with steroid inhalers added to manage symptoms and prevent exacerbations. Patients with more severe breathlessness (usually Medical Research Council (MRC) Grade 3 or worse, dyspnoea) are eligible for pulmonary rehabilitation (PR). All patients should receive influenza and pneumococcal vaccines, and advice about self-management (Bolton 2013; Vogelmeier 2017). In practice, evidence from the literature suggests that patients are often not appropriately managed, with over and under prescription of inhalers, and under-utilisation of other effective services (Perez 2011; Price 2014).
Details of pulmonary rehabilitation
Pulmonary rehabilitation (PR) is a structured multidisciplinary programme defined as 'an interdisciplinary programme of care for patients with chronic respiratory impairment that is individually tailored and designed to optimise each patient's physical and social performance and autonomy. Programmes comprise individualised exercise programmes and education' (Bolton 2013). One of the main aims of PR is to increase physical activity for those with COPD (Spruit 2013). Increasing physical activity requires behaviour change. PR emphasizes behaviour change through patient and interdisciplinary collaboration, and it is this collaborative approach that is key in achieving increasing physical activity in patients with COPD, over exercise-only interventions (Spruit 2015). PR programmes are commonly delivered to groups of patients in community or hospital settings, although other models of delivery, including home-based programmes, are also available. Evidence that supports home-based PR as an alternative, yet effective PR approach for COPD patients, is an emerging field (Grosbois 2015; Mohammadi 2013). Recommendations state that for optimal effectiveness, programmes should run twice weekly for a minimum of six weeks (Bolton 2013; Vogelmeier 2017), although programmes that run twice weekly for a minimum for eight weeks are recommended by other guidelines (Rochester 2015 (Steiner 2015) . Reasons given for low patient referral by healthcare practitioners included a lack of knowledge about programme content, challenging or uncertain referral process (or both), time pressures for the prospective referrer, uncertainty of whose role it was to refer, and anticipated access difficulties for patients (Foster 2016; Harris 2008a; Johnston 2013). Conclusions from these studies were that these difficulties disempowered the healthcare practitioner (HCP), and that increasing knowledge of PR and its benefits would improve referral rates.
Attendance at pulmonary rehabilitation
Following referral, patients are required to attend a PR pre-assessment. This is commonly completed by the PR staff and includes a full patient history, physical examination, assessment of contraindications and risk factors, such as unstable cardiovascular disease (unstable angina, unstable arrhythmias, aortic aneurysm, hypertension), or other inhibiting conditions, such as severe arthritis or neurological conditions (Bolton 2013; Spruit 2013). It is also a time during which a detailed description of the programme is provided, and discussions about individual patient goals, motivations, expectations, including barriers and capabilities, should be discussed (Vogelmeier 2017). In the England and Wales audit, it was reported that of the 68,000 COPD patients referred, 47,020 (69%) attended pre-assessment, following which, 10% to 14.8% of patients did not enrol in PR 
Description of the intervention
The purpose of this review is to focus on interventions to improve referral, uptake, and adherence to pulmonary rehabilitation by COPD patients, which is already recommended as an effective service. Interventions identified in scoping reviews have identified that increasing HCP knowledge, and support to COPD patients to manage co-morbidities, such as anxiety and depression, improved patient uptake to PR (Hardy 2014). A quasi-randomised trial sought to increase patient empowerment by using tablet devices with a personal training diary. Investigators observed improvements in PR adherence in this intervention group compared with usual care (Ringbaek 2016). Interventions may use a variety of delivery platforms, including digital technologies, avatar-based technologies and videos, or more traditional, written information, paying attention to the verbal and written language used (Johnston 2013; Williams 2011). The use of 'lay' advocates, such as 'expert patients' may also play a key role.
The intervention may use a variety of direct or indirect behaviour change approaches, either separately or in combination, targeted at each step or audience. The intervention may target the patient, their HCP, partner, family members, caregivers, friends, or a combination. Within the behaviour change approaches, it is likely the interventions will seek to address capability, opportunity, or motivation issues within each of the specified participant groups (Michie 2013). This may, for example, include increasing the opportunities to discuss or access PR programmes; it may also include strategic interventions, which enhance referral processes or increase awareness of PR programmes and their benefits.
Why it is important to do this review
COPD is an increasing global public health issue, with a high burden of morbidity and mortality (Lozano 2012; Murray 2015). PR is a clinically effective and cost effective intervention that can reduce mortality and improve prognosis. However, referral to pulmonary rehabilitation programmes, and uptake and adherence rates are universally low. Interventions to tackle each of these outcomes will benefit patients' physical and psychological well-being, and reduce the use of unplanned and emergency healthcare services. There is only one similar systematic review that has been published, which investigated interventions that sought to improve the uptake and completion of pulmonary rehabilitation in COPD (Jones 2017). This systematic review included only randomised controlled trials, of which there was only one (Ringbaek 2016). They concluded that they could not make any recommendations for practice. Three UK trials are currently underway, and there are non-randomised studies available, which will inform the evidence base and warrant inclusion. There is also a systematic review that investigated interventions that increased uptake and adherence to cardiac rehabilitation for patients with coronary heart disease, including heart failure. This review reported limited evidence supporting intervention effectiveness within this field (Karmali 2014). Similar to Jones 2017, this systematic review only included RCTs. Given the ongoing studies within in the pulmonary rehabilitation field, and the lack of evidence reported by previous systematic reviews that only included RCTs, this proposed systematic review, which will be regularly updated to include new evidence and will have clinical benefit for those with COPD and their caregivers.
O B J E C T I V E S
To determine the effectiveness of interventions to increase patient referral, uptake, and adherence to pulmonary rehabilitation programmes, for patients with COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We anticipate that there will be limited trials available, therefore, we will include a broad range of study designs including: randomised controlled trials (RCT; individual or cluster-level) and observational studies, such as non-randomised controlled trials (including controlled before-and-after studies and non-controlled, before-and-after studies). We will include studies reported in full text, those published as an abstract only, and unpublished data. We will not apply any restrictions.
Types of participants Inclusion criteria
Interventions to improve referral, uptake, and adherence rates may be applied to healthcare professionals or patients, partners, caregivers, family, or friends of the COPD patient. Therefore, we will include studies in which the population is either: 1. Healthcare practitioners (of any age) who care for patients with either stable or acute COPD, in all healthcare settings. Or: 2. Adult participants (at least 18 years of age) who have a primary diagnosis of COPD, defined with or without spirometric confirmation. We will include studies in which the participants have any stage of COPD, with either stable disease or post-acute exacerbations, and who may have singular or multiple co-morbidities. There will be no upper age limit. Or: 3. Partners, caregivers, family, or friends (of any age), of the COPD patient, who may influence referral, uptake, or adherence to pulmonary rehabilitation.
Exclusion criteria
We will exclude studies in which the focus of the study is on participants receiving PR with the following primary diagnoses: asthma, bronchiectasis, lung cancer, interstitial lung disease (ILD), and congestive cardiac failure. We will exclude interventions that are designed to target other programmes, such as maintenance pulmonary rehabilitation programmes.
Types of interventions
Interventions will be eligible if they aim to increase referral to, uptake of, or adherence to any type of PR programme. Potential comparators could be usual care, or any concurrent control group that was not receiving an intervention that aimed to improve referral, uptake, or adherence to PR, or alternative intervention to improve referral/uptake/adherence.
Types of outcome measures

Primary outcomes
1. Referral to pulmonary rehabilitations programmes (as measured by referral sent or received)
2. Attendance at pulmonary rehabilitation programme assessment 3. Attendance at start of pulmonary rehabilitation programme 4. Adherance to pulmonary rehabilitation programme (as specified by study reports, but usually percent % of sessions attended) We will present outcomes as proportions. Rationale. In order to access and enrol in PR, patients are initially referred by a HCP, or in some circumstances, the patient may selfrefer. Attending a PR assessment is the next step, which if successful, is followed by an opportunity to start a PR programme. Adequate attendance at PR programmes is essential in order to gain clinical and psychosocial benefits, however, the literature informs us that these steps are areas of weakness in PR recruitment and retention. Interventions designed to increase uptake and sustainability at each stage are emerging. Identifying those that are effective is a key aim of the systematic review.
Secondary outcomes
There are no secondary outcome measures for this review.
Search methods for identification of studies Electronic searches
We will search for randomised controlled trials in the Cochrane Airways Trials Register, which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from several sources (see Appendix 1 for details). We will conduct additional searches of the following databases, using appropriate search terms to identify both randomised and non-randomised trials:
1 5. PEDro (Physiotherapy Evidence Database; search date) We have described the proposed CENTRAL and MEDLINE search strategies in Appendix 2. We will adapt them for the other databases. We will search all databases from their inception to the present, and there will be no restriction on language of publication. We will search handsearched conference abstracts and grey literature through the CENTRAL database and the Cochrane Airways Trials Register. We will search the following trials registries:
1 
Searching other resources
We will check the reference lists of all primary studies and review articles for additional references. We will search relevant manufacturers' websites for study information. We will search for errata or retractions from included studies published in full text on PubMed and report the date this was done in the review.
Data collection and analysis
Selection of studies
Two review authors (JY and RJ) will independently screen the titles and abstracts of the search results and code them as 'retrieve' (eligible or potentially eligible or unclear) or 'do not retrieve'. We will retrieve the full-text study reports of all potentially eligible studies, and two review authors (JY and RA) will independently screen them for inclusion, recording the reasons for exclusion of ineligible studies. We will resolve any disagreement through discussion, or if required, we will consult a third review author (PA). We will identify and exclude duplicates and collate multiple reports of the same study, so that each study, rather than each report, is the unit of interest in the review. We will record the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (Moher 2009).
Data extraction and management
We will use a pre-designed data collection form for these study characteristics and outcome data, which will be piloted on at least one study in the review.
1. Methods: study design, aim of study, total duration of study, details of any 'run-in' period, number of study centres and location, study setting, withdrawals, and date of study. Study inclusion and exclusion criteria 2. COPD patients: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, medication, prior history of PR 3. Healthcare practitioner: N, mean age, gender, job role, length of time in job role, contracted hours in job role, prior academic experience, knowledge of and experience with PR 4. Interventions: type of behaviour change intervention, duration of intervention and comparator, description of target PR service 5. Outcomes: primary and secondary outcomes specified and collected, and time points reported 6. Notes: funding for studies, and notable conflicts of interest of trial authors. Two review authors (JY and RJ) will independently extract outcome data from included studies. We will note in the 'Characteristics of included studies' table if outcome data were not reported in a usable way. We will resolve disagreements by consensus, or by involving a third review author (PA). One review author (JY) will transfer data into the Review Manager 5 file (RevMan 2014). We will double-check that data are entered correctly by comparing the data presented in the systematic review with the study reports. A second review author (AE) will spot-check study characteristics for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (JY and RJ) will independently assess risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will resolve any disagreements by discussion or by involving another author (PA). We will assess the risk of bias according to the following domains:
1. random sequence generation; 2. allocation concealment; 3. blinding of participants and personnel; 4. blinding of outcome assessment; 5. incomplete outcome data; 6. selective outcome reporting; 7. other bias. We will judge each potential source of bias as high, low, or unclear, and provide a quote from the study report and a justification for our judgement in the 'Risk of bias' table. We will summarise the risk of bias judgements across different studies for each of the domains listed. We will consider blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for objectively recorded PR attendance may be different than for patient-reported attendance). Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the 'Risk of bias' table. When considering treatment effects, we will take into account the risk of bias for the studies that contribute to that outcome. Methodological quality or risk of bias for non-randomised studies will be assessed using the ROBINS-I tool (Sterne 2016). When including non-randomised studies, we will assess whether the authors have accounted for potential confounding factors including characteristics of the patients (e.g. age, sex, ethnicity, smoking status, severity of disease, co-morbidities, prior attendance at PR, caring responsibilities, distance from programme) and characteristics of the healthcare professionals (type, experience, age, academic history).
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol, and justify any deviations from it in the 'Differences between protocol and review' section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR), and continuous data as the mean difference (MD) or standardised mean difference (SMD). We will undertake meta-analyses of RCTs and CCTs only when this is meaningful; that is, if the treatments, participants, outcomes, and the underlying clinical question are similar enough for pooling to make sense. We will use RevMan 5 software to calculate pooled effect sizes, to test for heterogeneity, and to perform subgroup analysis (RevMan 2014). We will only combine RCTs and CCTs if there is minimal clinical and methodological diversity between the controlled studies. If there is large heterogeneity, we will explore reasons for it, including undertaking subgroup analyses of the RCTs and CCTs separately. We will use a narrative format to describe skewed data (for example, as medians and interquartile ranges for each group). For non-controlled before and after studies we intend to describe the presence of the study and describe the results together with caveats about the lack of control group. It is likely that only end point studies will be available.
Unit of analysis issues
The unit of analysis will be the patient, and/or the healthcare practitioner. We will only meta-analyse data from cluster-RCTs if the available data have been adjusted (or can be adjusted), to account for the clustering. For cluster-randomised trials, we will make adjustments to the sample sizes for each intervention, based on the method described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We will contact investigators or study sponsors to verify key study characteristics and obtain missing numerical outcome data where needed (e.g. when a study is identified as an abstract only). When this is not possible, and the missing data are thought to introduce serious bias, we will take this into consideration in the GRADE rating for affected outcomes. When we identify relevant studies of mixed populations with no subgroup data, we will contact the study authors to request them. If we are still unable to acquire these data, and if less than 80% of the participants are from the population of interest, we will describe these studies in a narrative format, but exclude them from meta-analyses.
Assessment of heterogeneity
If appropriate we will use the I² statistic to measure heterogeneity among the studies in each analysis. We will consider an I 2 value greater than 50% to indicate substantial statistical heterogeneity, we will report it and explore the possible causes by pre-specified subgroup analysis (see below).
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and examine a funnel plot to explore possible small study and publication biases.
Data synthesis
We will use a random-effects model and perform a sensitivity analysis with a fixed-effect model (if appropriate).
'Summary of findings' table
We will create a 'Summary of findings' table with the following outcomes: referral to pulmonary rehabilitations programmes, attendance at PR programme assessment, attendance at start of PR programme, and attendance for the duration of PR programme. We will use the five GRADE considerations (risk of bias, indirectness, consistency of effect, imprecision, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data for the pre-specified outcomes. We will use the methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), and GRADEpro software (GRADEpro GDT). We will justify all decisions to downgrade the quality of studies in footnotes, and we will make comments to aid the reader's understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses where possible: 1.Type of referring healthcare practitioner (nurse, doctor, other) Rationale: the type of healthcare practitioner could influence whether patients are referred, and the likelihood of uptake and adherence after referral. 2. Origin of referral (self, community, hospital) Rationale. Motivation for adherence and completion may vary according to who made the referral. 3.Pulmonary rehabilitation programme setting (home versus centre-based) Rationale. Perceived convenience of attending has been highlighted as a barrier to attendance in qualitative studies. Therefore, the setting could influence uptake, adherence, or completion. 4.Patient age (up to 65 years, over 65 years) Rationale. Patient age and working status are reported to be an influencing characteristic, particularly in adherence. The age cutoff is based on approximate age for retirement. 5. COPD severity (as determined by stable disease or post-exacerbation) Rationale. Motivation to attend and complete may differ according to whether the patient has had a recent exacerbation. We will use the following outcomes in subgroup analyses:
1. Referral to PR programmes (as measured by study reports); 2. Attendance at PR programme assessment (as measured by study reports);
3. Attendance at start of PR programmes (as measured by study reports);
4. Adherence to PR programmes (as measured by study reports). We will use the formal test for subgroup interactions in Review Manager 5 (RevMan 2014).
Sensitivity analysis
We will undertake sensitivity analyses, where possible to
• compare the results from a fixed-effect model with the random-effects models;
• restrict the analyses to those with an active comparator only;
• if only non-randomised controlled clinical trials are available, remove studies that are at 'serious' or 'critical' risk of bias, according to the ROBINS-I tool We will exclude RCT studies with high risk of bias (two or more domains judged to be at high risk of bias).
A C K N O W L E D G E M E N T S
The Background and Methods sections of this protocol are based on a standard template used by Cochrane Airways.
